Article Sidebar
Views PDF: 88
ANALYZING PROGNOSTIC FACTORS OF RECURRENT/METASTATIC PULMONARY LARGE CELL NEUROENDOCRINE CARCINOMA PATIENTS TREATED WITH FIRST-LINE CISPLATIN PLUS ETOPOSIDE CHEMOTHERAPY
Main Article Content
Abstract
Objective: Evaluating the survival outcomes and analyzing prognostic factors of recurrent/ metastatic pulmonary large cells neuroendocrine carcinoma patients treated with cisplatin plus etoposide chemotherapy at Vietnam National Cancer Hospital from 1/2018 to 10/2021. Patients and Methods: A retrospective study of 33 patients diagnosed of recurrent/ metastatic pulmonary large cells neuroendocrine carcinoma were treated with first-line Cisplatin plus etoposide chemotherapy at Vietnam National Cancer Hospital from 1/2018 to 10/2021. Results: Median progression-free survival was 5 ±0.61 months, median overall survival was 12 ±1.354 months. Patients diagnosed of £ 2 metastatic organs had a higer median OS than one with over 2 metastatic organs, 14.5 months versus 8.9 months, there was a significant difference between two groups with p=0.041. Median OS of patients presented with ECOG 0 and 1-2 were 15.8 months and 8.2 months, respectively and there was a report of a significant difference with p=0.048. Age, gender and smoking condition did not affect the overall survival. Conclusion: Cisplatin plus etoposide chemotherapy for recurrent/metastatic stages in large cell neuroendocrine lung carcinoma had a improvement survival outcome with a median of 12 ±1,354 months, and the number of metastatic organs and performance status were two factors affected survival outcome.
Article Details
Keywords
Pulmonary large cell neuroendocrine, cisplatin plus etoposide
References
2. Travis WD, Linnoila RI và cộng sự. Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma. An ultrastructural, immunohistochemical, and flow cytometric study of 35 cases. Am J Surg Pathol. 1991;15:529–53.
3. Travis WD, Rush W và cộng sự. Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. Am J Surg Pathol. 1998;22:934–44.
4. Lara PN, Jr, Natale R và cộng sự. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol. 2009;27:2530–5..
5. Yamazaki S, Sekine I và cộng sự. Clinical responses of large cell neuroendocrine carcinoma of the lung to cisplatin-based chemotherapy. Lung Cancer. 2005;49:217–23.
6. Le Treut J, Sault MC và cộng sự. Multicentre phase II study of cisplatin-etoposide chemotherapy for advanced large-cell neuroendocrine lung carcinoma: the GFPC 0302 study. Ann Oncol. 2013;24:1548–52
7. Niho S, Kenmotsu H, Sekine I, et al. Combination chemotherapy with irinotecan and cisplatin for large-cell neuroendocrine carcinoma of the lung: a multicenter phase II study. J Thorac Oncol. 2013;8:980–4.
8. Shimada Y, Niho S, Ishii G, et al. Clinical features of unresectable high-grade lung neuroendocrine carcinoma diagnosed using biopsy specimens. Lung Cancer. 2012;75:368–73.
9. Christian Roesel, Stefan Welter, Karl-Otto Kambartel et al. Prognostic markers in resected large cell neuroendocrine carcinoma: a multicentre retrospective analysis. J Thorac Dis. 2020 Mar; 12(3): 466–476.
10. Elisa Andrini, Valentina Tateo, Dario De Biase et al. Large cell neuroendocrine carcinoma of the lung: Prognostic factors to predict clinical outcomes. Meeting Abstract, 2021 ASCO Annual Meeting I.